{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:18:40Z","timestamp":1793056720534,"version":"4.5.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite effective antiretroviral therapy (ART), people with HIV (PWH) experience persistent immune activation and inflammation, increasing the risk of non-AIDS-related comorbidities. The contribution of the HIV reservoir to this chronic inflammatory state remains debated. Understanding the relationship between HIV persistence, immune activation, and inflammation is crucial for optimizing long-term therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study assessed HIV persistence, immune activation, and systemic inflammation in 49 PWH treated with the same dolutegravir-based triple ART regimen. HIV reservoir size and activity were evaluated by measuring total HIV DNA in peripheral blood mononuclear cells (PBMCs) and rectal tissue, cell-associated (CA) unspliced (US) HIV RNA, and residual viremia. Over 20 inflammatory biomarkers, including sCD14, IL-6, TNF-\u03b1, and CXCL10, were analyzed, along with comprehensive immune profiling using a 26-color spectral flow cytometry panel. Clinical parameters such as age, nadir CD4 count, and co-infections were also considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>Our findings showed a limited association between HIV persistence markers and systemic inflammation or immune activation. Compared to previous studies, participants had lower reservoir sizes and transcriptional activity, likely due to early ART initiation and prolonged suppression. Immune preservation was evident, with high CD4\/CD8 ratios and reduced activation markers. These results challenge the idea that the HIV reservoir is the primary driver of chronic inflammation in PWH on a dolutegravir-based long-term ART. Instead, the reservoir may evolve toward a more transcriptionally silent and defective state, reducing its impact on systemic immune activation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1628086","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:31:01Z","timestamp":1753680661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["No associations between HIV reservoir and inflammation in long-term virally suppressed dolutegravir-based ART-treated individuals"],"prefix":"10.3389","volume":"16","author":[{"given":"C\u00e9line","family":"Fombellida-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Aguilar Ortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Moutschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander O.","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Darcis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"B1","unstructured":"Fact sheet, HIV and AIDS\n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-012-0118-8","article-title":"HIV and inflammation: mechanisms and consequences","volume":"9","author":"Hunt","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12064","article-title":"Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs","volume":"254","author":"Wilson","year":"2013","journal-title":"Immunol Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/JLB.4MR1019-189R","article-title":"Incomplete immune reconstitution in HIV\/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders","volume":"107","author":"Yang","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11904-017-0356-x","article-title":"Inflammation, immune activation, and antiretroviral therapy in HIV","volume":"14","author":"Hileman","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6825493","DOI":"10.1155\/2017\/6825493","article-title":"HIV as a cause of immune activation and immunosenescence","volume":"2017","author":"Sokoya","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/hiv.12310","article-title":"Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy","volume":"17","author":"Younas","year":"2016","journal-title":"HIV Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-050520-112001","article-title":"In vivo dynamics of the latent reservoir for HIV-1: new insights and implications for cure","volume":"17","author":"Siliciano","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101301","DOI":"10.1016\/j.coviro.2023.101301","article-title":"HIV persistence: silence or resistance","volume":"59","author":"Pasternak","year":"2023","journal-title":"Curr Opin Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12065","article-title":"Immune activation and HIV persistence: implications for curative approaches to HIV infection","volume":"254","author":"Klatt","year":"2013","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/COH.0000000000000230","article-title":"Residual inflammation and viral reservoirs: alliance against an HIV cure","volume":"11","author":"Massanella","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral\u00a0therapy","volume":"11","author":"Martinez-Picado","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"B15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7316456","DOI":"10.1155\/2021\/7316456","article-title":"HIV-related immune activation and inflammation: current understanding and strategies","volume":"2021","author":"Lv","year":"2021","journal-title":"J Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0185761","DOI":"10.1371\/journal.pone.0185761","article-title":"Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium","volume":"12","author":"De Voeght","year":"2017","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"104182","DOI":"10.1016\/j.ebiom.2022.104182","article-title":"Dissecting drivers of immune activation in chronic HIV-1 infection","volume":"83","author":"Streeck","year":"2022","journal-title":"EBioMedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PloS Pathog"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123342","article-title":"Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy","volume":"14","author":"Chiu","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738743","article-title":"Antigen presenting cells contribute to persistent immune activation despite antiretroviral therapy initiation during hyperacute HIV-1 infection","volume":"12","author":"Naidoo","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"105338","DOI":"10.1016\/j.ebiom.2024.105338","article-title":"HIV-1-DNA\/RNA and immunometabolism in monocytes: contribution to the chronic immune activation and inflammation in people with HIV-1","volume":"108","author":"Mu\u00f1oz-Muela","year":"2024","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B24","article-title":"Aging, inflammation, and HIV infection","volume":"20","author":"Aberg","year":"2012","journal-title":"Top Antivir Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12979-021-00260-x","article-title":"The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study","volume":"19","author":"Chen","year":"2022","journal-title":"Immun Ageing"},{"key":"B26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/biomedicines11010159","article-title":"The many faces of immune activation in hiv-1 infection: a multifactorial interconnection","volume":"11","author":"Mazzuti","year":"2023","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy617","article-title":"Sex-based differences in human immunodeficiency virus type 1 reservoir activity and\u00a0residual immune activation","volume":"219","author":"Scully","year":"2019","journal-title":"J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e180075","DOI":"10.1172\/JCI180075","article-title":"The impact of sex on HIV immunopathogenesis and therapeutic interventions","volume":"134","author":"Mihealsick","year":"2024","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.106931.1","article-title":"Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV","author":"Fombellida-Lopez","year":"2009"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5264475","article-title":"Impact of Abacavir Withdrawal from a Triple ART Regimen on HIV Reservoir and Systemic Inflammation: A Phase 3 Randomised Controlled Trial","author":"Fombellida-Lopez","year":"2025","journal-title":"SSRN Scholarly Paper"},{"key":"B31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix039","article-title":"Human immunodeficiency virus persistence and T-cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus\u2013infected individuals receiving suppressive antiretroviral therapy","volume":"215","author":"Khoury","year":"2017","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis630","article-title":"Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)\u2013expressing CD4+ T cells","volume":"208","author":"Hatano","year":"2013","journal-title":"J Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e110731","DOI":"10.1371\/journal.pone.0110731","article-title":"CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells","volume":"9","author":"Cockerham","year":"2014","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa657","article-title":"HIV-1 transcription but not intact provirus levels are associated with systemic inflammation","volume":"223","author":"Olson","year":"2021","journal-title":"J Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00099-21","article-title":"Cell-associated HIV-1 unspliced-to-multiply-spliced RNA ratio at 12 weeks of ART predicts immune reconstitution on therapy","volume":"12","author":"Scherpenisse","year":"2021","journal-title":"mBio"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e26320","DOI":"10.1371\/journal.pone.0026320","article-title":"Association of low level viremia with inflammation and mortality in HIV-infected adults","volume":"6","author":"Eastburn","year":"2011","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182745ab0","article-title":"Low-level HIV viremia is associated with microbial translocation and inflammation","volume":"62","author":"Reus","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663843","article-title":"Residual viremia is linked to a specific immune activation profile in HIV-1-infected adults under efficient antiretroviral therapy","volume":"12","author":"Younas","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv433","article-title":"Continued\u00a0slow decay of the residual plasma viremia level in HIV-1-infected adults receiving long-term antiretroviral therapy","volume":"213","author":"Riddler","year":"2016","journal-title":"J Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12879-017-2676-2","article-title":"Evaluation\u00a0of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns","volume":"17","author":"Falasca","year":"2017","journal-title":"BMC Infect Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"Buzon","year":"2010","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ef7bb","article-title":"Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy","volume":"24","author":"Yukl","year":"2010","journal-title":"AIDS"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit453","article-title":"Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial","volume":"208","author":"Hatano","year":"2013","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1917","article-title":"Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study","volume":"17","author":"Llibre","year":"2012","journal-title":"Antivir Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283584521","article-title":"The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients","volume":"26","author":"Vallejo","year":"2012","journal-title":"AIDS"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e27864","DOI":"10.1371\/journal.pone.0027864","article-title":"Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected","volume":"6","author":"Guti\u00e9rrez","year":"2011","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000066","article-title":"Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection","volume":"28","author":"Puertas","year":"2014","journal-title":"AIDS"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky106","article-title":"Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs","volume":"73","author":"Puertas","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1086\/650749","article-title":"Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy","volume":"50","author":"McMahon","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1000321","DOI":"10.1371\/journal.pmed.1000321","article-title":"The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial","volume":"7","author":"Gandhi","year":"2010","journal-title":"PloS Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31823fd1f2","article-title":"No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy","volume":"59","author":"Gandhi","year":"2012","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000810","article-title":"Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery","volume":"29","author":"Cillo","year":"2015","journal-title":"AIDS"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01589-17","article-title":"Size, composition, and evolution of HIV DNA populations during early antiretroviral therapy and intensification with maraviroc","volume":"92","author":"Chaillon","year":"2018","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30040-7","article-title":"The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial","volume":"5","author":"Rasmussen","year":"2018","journal-title":"Lancet HIV"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/135965350701200613","article-title":"HIV-1 viral replication below 50 copies\/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation","volume":"12","author":"Steel","year":"2007","journal-title":"Antivir Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir208","article-title":"Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy","volume":"204","author":"Chun","year":"2011","journal-title":"J Infect Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835a5c2f","article-title":"Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials","volume":"26","author":"Mexas","year":"2012","journal-title":"AIDS"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23679","article-title":"Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen","volume":"85","author":"Allavena","year":"2013","journal-title":"J Med Virol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.04.007","article-title":"Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years","volume":"57","author":"Poizot-Martin","year":"2013","journal-title":"J Clin Virol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000815","article-title":"Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia","volume":"30","author":"Guihot","year":"2016","journal-title":"AIDS"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1006285","DOI":"10.1371\/journal.ppat.1006285","article-title":"Levels of HIV-1 persistence on antiretroviral therapy are\u00a0not\u00a0associated with markers of inflammation or activation","volume":"13","author":"Gandhi","year":"2017","journal-title":"PloS Pathog"},{"key":"B64","doi-asserted-by":"publisher","first-page":"jiae530","DOI":"10.1093\/infdis\/jiae530","article-title":"Impact of dolutegravir plus lamivudine as first-line antiretroviral treatment on HIV-1 reservoir and inflammatory markers in peripheral blood","volume":"231","author":"Bail\u00f3n","year":"2024","journal-title":"J Infect Dis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/v14050927","article-title":"Inflammatory markers after switching to a dual drug regimen in HIV-infected subjects: A two-year follow-up","volume":"14","author":"Vassallo","year":"2022","journal-title":"Viruses"},{"key":"B66","doi-asserted-by":"publisher","first-page":"ofad626","DOI":"10.1093\/ofid\/ofad626","article-title":"Very-low-level viremia, inflammatory biomarkers, and associated baseline variables: three-year results of the randomized TANGO study","volume":"11","author":"Wang","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"ofac068","DOI":"10.1093\/ofid\/ofac068","article-title":"Changes in inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in antiretroviral therapy-experienced, virologically suppressed people with HIV-1: A systematic literature review","volume":"9","author":"Llibre","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003019","article-title":"Brief report: evaluation of inflammation and atherogenesis biomarkers\u00a0through 148 weeks postswitch to dolutegravir and rilpivirine in SWORD-1\/SWORD-2","volume":"91","author":"Llibre","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00647-17","article-title":"Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46\/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells","volume":"91","author":"Marras","year":"2017","journal-title":"J Virol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"111126","DOI":"10.1016\/j.celrep.2022.111126","article-title":"Immune correlates of HIV-1 reservoir cell decline in early-treated infants","volume":"40","author":"Hartana","year":"2022","journal-title":"Cell Rep"},{"key":"B71","doi-asserted-by":"publisher","first-page":"eaax7350","DOI":"10.1126\/scitranslmed.aax7350","article-title":"Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile","volume":"11","author":"Garcia-Broncano","year":"2019","journal-title":"Sci Transl Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.757846","article-title":"Natural killer cell receptors and ligands are associated with markers of HIV-1 persistence in chronically infected ART suppressed patients","volume":"12","author":"Ivison","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.ebiom.2020.102830","article-title":"Extremely low viral reservoir in treated chronically HIV-1-infected individuals","volume":"57","author":"G\u00e1lvez","year":"2020","journal-title":"EBioMedicine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1334236","article-title":"Low unspliced cell-associated HIV RNA in early treated adolescents living with\u00a0HIV on long suppressive ART","volume":"15","author":"G\u00e4rtner","year":"2024","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e183952","DOI":"10.1172\/JCI183952","article-title":"Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir","volume":"135","author":"Gonz\u00e1lez-Navarro","year":"2024","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.chom.2022.12.002","article-title":"Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy","volume":"31","author":"Lian","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B77","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41467-019-08431-7","article-title":"Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion","volume":"10","author":"Pinzone","year":"2019","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e2117630119","DOI":"10.1073\/pnas.2117630119","article-title":"Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing","volume":"119","author":"Cho","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01010-8","article-title":"Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure","volume":"22","author":"Armani-Tourret","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"19828","DOI":"10.7448\/IAS.17.4.19828","article-title":"Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens","volume":"17","author":"Wiesmann","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01902-19","article-title":"Detectability of HIV residual viremia despite therapy is highly\u00a0associated with treatment with a protease inhibitor-based combination antiretroviral therapy","volume":"64","author":"Darcis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B82","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/v12050489","article-title":"Differences in HIV markers between infected individuals treated with different ART regimens: implications for the persistence of viral reservoirs","volume":"12","author":"Darcis","year":"2020","journal-title":"Viruses"},{"key":"B83","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12866-024-03431-0","article-title":"Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy","volume":"24","author":"Ishizaka","year":"2024","journal-title":"BMC Microbiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e0308859","DOI":"10.1371\/journal.pone.0308859","article-title":"HIV, the gut microbiome and clinical outcomes, a systematic review","volume":"19","author":"Mac Cann","year":"2024","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1628086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:31:03Z","timestamp":1753680663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1628086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2025.1628086"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1628086","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"article-number":"1628086"}}